How KYMRIAH May Help

Individualized just for you

KYMRIAH® (tisagenlecleucel) is not a pill, chemotherapy, or transplant. KYMRIAH is an individualized treatment made just for you, using the inner strength of your own immune system to fight your cancer. By reprogramming your T cells, KYMRIAH enhances their ability to detect and destroy your B cells, including those with cancer in them.

How well does KYMRIAH work?

Studies first began in 2012, and Novartis has since treated many patients with CAR-T therapy. Since 2015, KYMRIAH has been studied in a global clinical trial of children and young adults with relapsed or refractory B-cell ALL, with many achieving an early and lasting remission. KYMRIAH was approved based on the clinical trial data shown below. Click each button below to view this data, as well as the most recent 2-year data from the KYMRIAH clinical trial. While many patients have been successfully treated with KYMRIAH, not all patients will respond the same way.

The clinical trial data upon which KYMRIAH was approved showed that 83% (52 of 63) of children and young adults treated with KYMRIAH had their cancer go into remission. A long-term 2-year follow-up from the same study showed that 82% (65 of 79) of children and young adults treated with KYMRIAH had their cancer go into remission.

Doctors can use highly sensitive tests to look for traces of cancer in bone marrow called minimal residual disease or MRD. These tests give a very precise measure of remission that may indicate to your treatment team how well KYMRIAH is working.

The clinical trial data upon which KYMRIAH was approved showed that 100% (52 of 52) of children and young adults in remission after KYMRIAH had undetectable levels of cancer left in their bone marrow (MRD–). A longer term 2-year follow-up from the same study showed that 98% (64 of 65) of children and young adults in remission after KYMRIAH achieved this MRD– status.

The clinical trial data upon which KYMRIAH was approved showed that 88% (46 of 52) of children and young adults who achieved remission after treatment with KYMRIAH did not receive an allogeneic transplant. A longer term 2-year follow-up from the same study showed that 88% (57 of 65) of patients who achieved remission after KYMRIAH did not receive a transplant.

• The clinical trial data upon which KYMRIAH was approved showed that children and young adults have a 75% estimated chance of still being in remission 6 months after achieving remission. A longer term follow-up of the same study showed that children and young adults have a 62% estimated chance of still being in remission 2 years after achieving remission. Trials are still ongoing to see how long remissions last
• The clinical trial data upon which KYMRIAH was approved showed that children and young adults have an 89% estimated chance of still being alive 6 months after infusion. A longer term follow-up of the same study showed that children and young adults have a 66% estimated chance of still being alive 2 years after infusion. Trials are still ongoing to see if patients live longer with treatment

KYMRIAH for Kids
How has KYMRIAH helped kids like me?

KYMRIAH has helped kids with the same type of cancer that you have. Not everyone's experience is the same but, for many kids, it helped them beat their cancer.

 

Patient-reported quality of life

Some patients who have received KYMRIAH have reported improvements in certain aspects of their quality of life. Two different patient-reported surveys were used to measure quality of life. These surveys were given to patients before treatment with KYMRIAH and again at 3, 6, and 12 months after infusion. In these surveys, some patients reported improvements in mobility, pain/discomfort, anxiety/depression, and the ability to perform certain usual activities (such as going back to school). It is important to note that KYMRIAH is not approved to treat any of these measures of improvement and these results have not been confirmed by an additional study. Results can vary from patient to patient, and you may not experience improvements in your quality of life after receiving KYMRIAH. This information is not intended to provide medical advice, as your doctor understands the appropriate treatment for your particular condition best. You should talk to your doctor about what you may experience from treatment.